Figure 5.

Plasma levels of proHNPs, MPO and lysozyme in patients with AML. Peripheral blood samples were taken from 19 patients with AML at diagnosis before chemotherapy and 39 healthy controls. Levels of proHNPs (left), MPO (middle) and lysozyme (right) were measured by ELISA. ProHNPs were significantly lower in AML patients compared with healthy controls (P<0.0001). Levels of MPO and lysozyme did not differ significantly between patients and controls (MPO: P=0.55 and lysozyme: P=0.13). Differences were analyzed by Mann–Whitney U-test. AML, acute myeloid leukemia; HNP, human neutrophil peptides; MPO, myeloperoxidase; NGAL, neutrophil gelatinase-associated lipocalin.